Taysha Gene Therapies, Inc. is a clinical-stage gene therapy company focused on developing treatments for monogenic central nervous system diseases. Its lead product candidate, TSHA-102, targets Rett syndrome. The company leverages its gene therapy platform, including next-generation technologies, to identify and develop product candidates, with programs spanning preclinical studies and clinical trials.
expected 2026-11-10
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-19 | 2025-12-31 | 0001193125-26-115202 | EDGAR | 109K words |
| 2025-02-26 | 2024-12-31 | 0000950170-25-027348 | EDGAR | 108K words |
| 2024-03-19 | 2023-12-31 | 0000950170-24-033484 | EDGAR | 109K words |
| 2023-03-28 | 2022-12-31 | 0000950170-23-010343 | EDGAR | 97K words |
| 2022-03-31 | 2021-12-31 | 0001564590-22-012782 | EDGAR | — |
| 2021-03-03 | 2020-12-31 | 0001564590-21-010433 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-11 | 2026-06-30 | 0001193125-26-344610 | EDGAR | 33K words |
| 2025-11-04 | 2025-09-30 | 0001193125-25-263506 | EDGAR | 41K words |
| 2025-08-12 | 2025-06-30 | 0000950170-25-107010 | EDGAR | 41K words |
| 2025-05-15 | 2025-03-31 | 0000950170-25-072036 | EDGAR | 30K words |
| 2024-11-13 | 2024-09-30 | 0000950170-24-126416 | EDGAR | 42K words |
| 2024-08-12 | 2024-06-30 | 0000950170-24-095082 | EDGAR | 40K words |
| 2024-05-14 | 2024-03-31 | 0000950170-24-059555 | EDGAR | 34K words |
| 2023-11-14 | 2023-09-30 | 0000950170-23-063734 | EDGAR | 38K words |
| 2023-08-14 | 2023-06-30 | 0000950170-23-042089 | EDGAR | 40K words |
| 2023-05-11 | 2023-03-31 | 0000950170-23-021333 | EDGAR | 32K words |
| 2022-11-08 | 2022-09-30 | 0001564590-22-036936 | EDGAR | — |
| 2022-08-11 | 2022-06-30 | 0001564590-22-029155 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-08-11 | 0001193125-26-344594 | EDGAR | 4K words |
| 2026-03-19 | 0001193125-26-115177 | EDGAR | 3K words |
| 2025-11-04 | 0001193125-25-263543 | EDGAR | 4K words |
| 2025-10-16 | 0001193125-25-241415 | EDGAR | 1K words |
| 2025-10-09 | 0001193125-25-235212 | EDGAR | 2K words |
| 2025-10-02 | 0001193125-25-227505 | EDGAR | 2K words |
| 2025-08-12 | 0001193125-25-178504 | EDGAR | 4K words |
| 2025-06-03 | 0001193125-25-133745 | EDGAR | 1K words |
| 2025-05-29 | 0001193125-25-130709 | EDGAR | 5K words |
| 2025-05-28 | 0001193125-25-129494 | EDGAR | 5K words |
132 total filings indexed. 104 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001806310 |
| Ticker | TSHA |
| Exchange | Nasdaq |
| SIC | 2836: Biological Products, (No Diagnostic Substances) |
| Incorporated | DE |
| Website | https://www.tayshagtx.com |
| Listed | 2020-09-24 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/TSHA (~200 tokens, structured JSON with cryptographic provenance)